LEGN — Legend Biotech Cashflow Statement
0.000.00%
Last trade - 00:00
- $9.17bn
- $8.22bn
- $285.14m
- 56
- 12
- 45
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -130 | -308 | -386 | -446 | -520 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | -3.81 | 86 | 32.1 | 25.1 | 132 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 45.9 | -11.2 | 142 | 201 | -25.1 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -83.1 | -223 | -198 | -201 | -393 |
Capital Expenditures | -39.2 | -49.8 | -47.1 | -22.3 | -22.7 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -19.5 | 25.6 | -148 | -54.8 | 116 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -58.7 | -24.2 | -195 | -77.1 | 92.8 |
Financing Cash Flow Items | — | -2.51 | 0 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 14.7 | 619 | 627 | 378 | 791 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -127 | 372 | 233 | 97.1 | 492 |